SF

SFA Therapeutics

YC S21 ↗

Philadelphia, US · Founded 2016 · 4 employees · 6 known investors

sfatherapeutics.com ↗

SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.

Founders & leadership· Y Combinator alumni (S21)

IS

Ira SpectorinFounder

AA

Alla ArzumanyaninFounder

MF

Mark Feitelsonin𝕏Founder

Investors · 6

AC

Acequia Capital (AceCap)Seattle · $100K – $5M

FA

Farvatn VentureBergen

IM

ImmeasurableLos Angeles · $25K – $100K

Y

Y CombinatorSan Francisco · $500K

AC

Acequia CapitalreportedSeattle

BE

Ben Franklin Technology PartnersreportedHarrisburg · $50K – $250K